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Epigenetic reprogramming is a cancer hallmark, but how it unfolds during early neoplastic
events and its role in carcinogenesis and cancer progression is not fully understood. Here we
show that resetting from primed to naïve human pluripotency results in acquisition of a DNA
methylation landscape mirroring the cancer DNA methylome, with gradual hypermethylation
of bivalent developmental genes. We identify a dichotomy between bivalent genes that do
and do not become hypermethylated, which is also mirrored in cancer. We find that loss of
H3K4me3 at bivalent regions is associated with gain of methylation. Additionally, we observe
that promoter CpG island hypermethylation is not restricted solely to emerging naïve cells,
suggesting that it is a feature of a heterogeneous intermediate population during resetting.
These results indicate that transition to naïve pluripotency and oncogenic transformation
share common epigenetic trajectories, which implicates reprogramming and the pluripotency
network as a central hub in cancer formation.
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D isruption of DNA methylation patterns is a hallmark ofhuman cancers, typically characterised by loss of globalgenomic DNA methylation accompanied by site-specific
hypermethylation1–4. DNA hypomethylation is typically asso-
ciated with genomic instability5,6, while site-specific DNA
hypermethylation occurs at promoter CpG islands (CGIs) and
can be associated with repression of tumour suppressor genes in
cancer cells7,8. The majority of these observations have been
made in cancer cell lines or primary cancer cells, but they are not
fully representative of the processes occurring during the transi-
tion of normal cells into malignant cells. The underlying
mechanisms that give rise to these opposing patterns of genomic
DNA methylation in early stages of human cancer development
remain elusive, as does the timing and biological function of such
events in cancer initiation and progression. To this end, a recent
study demonstrated that ageing and cancer associated DNA
hypermethylation accelerates cellular transformation in a
BrafV600E mouse colon organoid system, through suppression of
Wnt signalling regulators in a progressive manner9. This study
functionally links promoter CGI hypermethylation with onco-
genic transformation, demonstrating a causal relationship.
Nevertheless, how de novo DNA methyltransferase activity is
preferentially targeted to specific regions of the genome in the
context of aberrant cancer methylation remains largely a mystery.
It has been hypothesised that cancer cells follow an evolu-
tionary trajectory towards a stem cell state, which allows both
self-renewal and differentiation10, and more recently, cancer-
related mutations have been identified in naive human embryonic
stem cells (hESCs)11.
Here we identify cancer-like DNA methylation changes during
primed to naïve hESC resetting using the recently developed
NANOG/KLF2 overexpression + 2iLGö method (comprising two
small-molecule inhibitors of MEK and GSK3β, human recombi-
nant leukaemia inhibitory factor, and a pan-PKC inhibitor)12.
Our system provides a unique opportunity to investigate the
mechanism of DNA hypermethylation in human cells in a tem-
poral manner, and sheds light on the role of the transcription
factor and pluripotency networks in driving cancer-like DNA
hypermethylation.
Results
Naïve resetting induces CGI promoter hypermethylation. To
investigate the kinetics of the changing DNA methylation land-
scape between primed and naïve hESCs, we transitioned primed
hESCs to the naïve state as previously described12, by inducing
NANOG/KLF2 transgenes with doxycycline. We also captured the
two intermediary states, termed ‘early transition’ and ‘late tran-
sition’ when the cells are in 2iL+dox or 2iL+Gö, respectively
(Fig. 1a). We see global DNA demethylation of the genome in
naïve cells as reported previously12, measured by the Infinium
MethylationEPIC array and mass spectrometry (Supplementary
Figs 1a–c). The loss of 5-methylcytosine (5mC) is gradual and is
accompanied by the loss of its oxidation product, 5-
hydroxymethylcytosine (5hmC) (Supplementary Fig. 1a). Inter-
estingly, while the majority of the genome is demethylated, we
observe hypermethylation of a subset of CpGs (an increase of
>10% methylation compared to primed hESCs), exemplified by
the HOXA cluster (Fig. 1b, c, Supplementary Fig. 1d). This gain
in methylation is evident as cells go through the early transition
of resetting, with a peak of hypermethylated CpGs as the cells go
through the late transition of resetting (Fig. 1b, c). Although the
peak of hypermethylation coincides with the cells being transi-
tioned into 2iL+ Gö conditions, the abundance of hypermethy-
lation is independent of the addition of Gö (Supplementary
Fig. 1e), indicating a time-dependent accrual of DNA methylation
instead. As the cells stabilise in the naïve state, we observe
maintenance of a proportion of hypermethylated sites, while
some CpGs show only a transient gain in methylation (Fig. 1b).
The reproducibility of the hypermethylation during the resetting
process is apparent from the strong overlap between hyper-
methylated sites across biologically independent Methylatio-
nEPIC arrays (with 2 or 3 cell populations assayed within each
array) and when compared to published whole-genome bisulfite
sequencing (WGBS) data, suggesting that the site-specific gain in
methylation is not random, and likely has a biological function
(Supplementary Figs 1f, g). Moreover, as primed hESCs and
hESCs during the early transition of resetting proliferate and cycle
at comparable rates as measured by loss of bromodeoxyuridine
(BrdU), the site-specific gain in methylation upon resetting is the
result of an active process rather than the selection of an existing
subpopulation of cells (Supplementary Fig 1h).
We next sought to investigate the genomic context with which
hypermethylation occurs. We utilised the Encyclopaedia of DNA
elements (ENCODE) ChIP-seq datasets for the H1 primed hESC
cell line and overlapped them with resetting-associated hyper-
methylated probes. We observed that hypermethylated probes are
enriched within regions marked by H3K4me1/2/3 and
H3K27me3 in primed hESCs (Fig. 1d). The majority of these
fall within regions marked by bivalent histone modifications,
defined by co-occurrence of H3K4me3 and H3K27me3 (Fig. 1e).
Bivalency typically marks regulatory regions (promoters and
enhancers with overlapping transcription factor binding sites)13,
and as expected, we saw a striking overlap with CGIs and
regulatory regions, which is not the case for hypomethylated
probes (Fig. 1f, g). In addition, the majority of the hypermethy-
lated probes reside within ChromHMM predicted poised
promoters (Fig. 1h). To validate our results, we also re-analysed
published whole-genome bisulfite sequencing data for primed
and naïve hESCs12, and identified 26,625 regions (300 bp each)
that were hypermethylated (>10% increase in naïve vs primed) in
naïve hESCs. In agreement with our Illumina MethylationEPIC
array data, we observed enrichment of these regions within loci
marked by bivalency in primed hESCs, with a bias towards
regulatory regions and CGIs (Supplementary Figs 2a–e). This
strongly reinforces the highly reproducible nature of the DNA
hypermethylation that occurs upon resetting of primed hESCs to
naïve pluripotency.
To eliminate the possibility that the hypermethylation is simply
an artefact of the NANOG/KLF2+ 2iLGö in vitro resetting
system, we compared 2iLGö naïve hypermethylated regions to
hypermethylated regions identified in naïve cells generated using
the alternative methods of naïve hESC generation and those in
the human inner cell mass (ICM)14–17. We saw a significant
overlap between the hypermethylated regions in each of these
datasets compared to the 2iLGö naïve cells, in both cases also
enriched within H3K4me1/2/3 and H3K27me3 regions in primed
hESCs (Supplementary Fig 3a–g). Interestingly, we do not detect
any hypermethylation in mouse embryonic stem cells cultured in
2i compared to those cultured in serum18, and the hypermethyla-
tion present in the mouse ICM19 is far less extensive and does not
enrich at bivalent regions (Supplementary Fig 3h–j). Overall from
these results, we can conclude that the hypermethylation pattern
is a feature of in vitro naïve human pluripotency and recapitulates
the in vivo relationship between the ICM and the post-
implantation embryo.
Developmental genes are hypermethylated and repressed. To
identify the genes targeted by hypermethylation, we performed
gene ontology (GO) analysis of the genes and classified a gene as
hypermethylated if it possessed a hypermethylated probe/ region
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within 1500 bp upstream of its transcription start site (TSS). GO
analysis revealed an extensive enrichment of hypermethylated
genes in developmental pathways, particularly neuronal devel-
opment, while hypomethylated genes show much weaker
enrichment in pathways involved in cell cycle and metabolism
(Fig. 2a, Supplementary Fig. 4a). To investigate whether hyper-
methylation is associated with gene silencing, we performed
temporal transcriptome analysis of cells during the transition
from primed to naïve pluripotency and observed thousands of
genes differentially expressed at each stage of the transition
compared to primed hESCs, with an enrichment of down-
regulated genes in developmental pathways (Supplementary
Fig 4b, c). We observed that the average expression of genes
which undergo hypermethylation is attenuated in naïve compared
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to primed hESCs, but that hypermethylated genes are char-
acterised by low average expression in primed hESCs (Fig. 2b, c).
Hypermethylation may play a functional role in these cells by
contributing to downregulation of developmental pathways,
perhaps enhancing pluripotency and blocking differentiation by
providing a more stable gene repression mechanism13. Intrigu-
ingly, we observe a subset of genes, notably the HOX gene family,
that become hypermethylated and are upregulated upon hESC
resetting (Fig. 2d), despite no evidence of 5mC oxidation to
5hmC at their promoters (Fig. 2e). Interestingly, the methylation
dynamics of these HOX genes do not differ from genes that are
hypermethylated and downregulated (Fig. 2c, d, Supplementary
Fig. 4d). This suggests that there may be population heterogeneity
during resetting, whereby a subpopulation of cells which do not
undergo HOX promoter hypermethylation exhibit upregulation
of the genes.
DNMT3A controls early de novo methylation. We next sought
to identify the epigenetic regulators that are responsible for the
deposition of de novo DNA methylation. Of the de novo DNMT3
family of DNA methyltransferases, DNMT3B is highly expressed
but is transiently downregulated upon resetting. The mRNA level
of DNMT3A is transiently upregulated (Supplementary Fig. 5a),
though this is not reflected in the protein level (Supplementary
Fig. 5g). The catalytically inactive DNMT3L is upregulated
(Supplementary Fig. 5a) and considered a marker of naïve plur-
ipotency20. We generated constitutive knockdown primed hESC
cell lines using two short hairpin RNAs (shRNAs) targeting each
of the three genes, as well as one specifically targeting the long
isoform of DNMT3A, known as DNMT3A1 (Supplementary
Fig. 5b). We subjected each of the cell lines to resetting until the
early transition, at which stage hypermethylation is already
detectable, and thereafter to the late transition. In the early
transition, knockdown of DNMT3B and DNMT3L had little
impact on the level of methylation (Fig. 3a, Supplementary
Fig. 5c). Knockdown of DNMT3A, however, was able to abolish
hypermethylation (Fig. 3a). A recent study demonstrated
isoform-specific recruitment of DNMT3A1 to bivalent CGIs in
mouse embryonic stem cells21. However, specific knockdown of
DNMT3A1 had no impact on the level of hypermethylation
(Supplementary Fig. 5d), suggesting that the more dominantly
expressed DNMT3A2 carries out de novo methylation early
during resetting, independently of DNMT3L. It is worth noting,
however, that during the late transition of resetting, both
DNMT3A and DNMT3B knockdown cells show a partial
reduction in methylation compared to the control cells (Fig. 3b).
This indicates that DNMT3B, which by this stage is tran-
scriptionally expressed at a higher level than during the early
transition (Supplementary Fig. 5a), contributes to hypermethy-
lation along with DNMT3A. Additionally, when we reset either
DNMT3A or DNMT3B knock down cells to the naïve state, we
see a reduction in the pluripotency of the cells as measured by
their alkaline phosphatase activity as well as reduced expression
levels of naïve pluripotency genes in DNMT3A but not DNMT3B
knock down cells (Fig. 3c, d, Supplementary Fig. 5e). As both
DNMT3A and DNMT3B seem to contribute to hypermethylation
during the late transition of resetting, we additionally generated a
double knock down cell line of the two genes in primed hESCs
and subjected the cells to resetting to the naïve state (Supple-
mentary Fig 5f). The DNMT3A/DNMT3B double knock down
cells show significantly reduced levels of hypermethylation during
the early transition as well as in naïve hESCs, and they exhibit
reduced pluripotency as measured by their alkaline phosphatase
activity and expression levels of naïve pluripotency genes, though
TFCP2L1 and KLF4 do not change significantly (Fig. 3e–g).
Collectively, this indicates a putative role of the de novo
methyltransferases in stabilisation of the naïve pluripotent state.
Aside from the de novo methyltransferases, we also hypothe-
sised that loss of ten-eleven translocation (TET) enzymes may be
the cause of bivalent CGI hypermethylation22,23. TET1 is expressed
in primed hESCs and subsequently downregulated at the protein
level as hESCs progress through the early transition of resetting
(Supplementary Fig 6a, b). We generated TET1-overexpressing
primed hESCs (Supplementary Fig 6c, d) and subjected them to
resetting until the early transition. We measured DNA methylation
at selected target loci but observed no change in the levels of DNA
methylation, though TET1 is modestly overexpressed (Supple-
mentary Fig. 6e). These data indicate that hypermethylation of
bivalent loci upon resetting is independent of TET1 loss.
To determine whether de novo methylation is strictly
correlated with the acquisition of naïve pluripotency during
resetting, we used a published cell-surface marker, SUSD2, that
has been shown to separate naïve from primed hESCs during
resetting24, and is able to identify increasing numbers of naïve
hESCs during the transition to the naïve state (Supplementary
Fig. 7a). We sorted SUSD2+ and SUSD2- cells during the early
and late transition of resetting and used a targeted approach to
measure DNA methylation at selected resetting-associated
hypermethylated loci (Fig. 4a). We observed no significant
difference in the level of hypermethylation in SUSD2+ and
SUSD2- fractions, though SUSD2+ cells displayed higher
expression of naïve pluripotency genes (Fig. 4b, c, Supplementary
Fig. 7b). In conjunction with the observation that reduced
expression of de novo methyltransferases during resetting
impacts naïve pluripotency, this indicates that while de novo
methylation may be important for the stability of the naïve
Fig. 1 Primed to naïve resetting induces bivalent CGI promoter hypermethylation. a Schematic detailing the model system and time points used in the
study. 2iL+dox: 2 small-molecule inhibitors of MEK1/2 and GSK3β (2i), human recombinant leukaemia inhibitory factor (hLIF; collectively 2iL) and
doxycycline. 2iL+Gö: 2iL and a pan-protein kinase C inhibitor (PKCi), Gö. hESCs, human embryonic stem cells. b Heatmap showing methylation levels of
the top 10,000 CpG probes that are differentially methylated (Δβ > 0.1, adjPval < 0.05) in the early transition, late transition and naïve hESCs compared to
primed hESCs. Methylation β-value is indicated by the colour key. adjPval based on Benjamini–Hochberg adjustment. c Genome browser tracks for Infinium
MethylationEPIC data capturing a representative hypermethylated locus. The heatmap shows the raw methylation β-values per CpG for each sample, while
the subsequent rows show the per-probe difference in methylation for each time point of resetting compared to primed hESCs. CGIs are highlighted in
green. d Overlap of hypermethylated probes (n= 91,119) with regions of histone modification enrichment (obtained from the ENCODE ChIP-seq data for
hESC cell line H1: H3K4me1 n= 139971; H3K4me2 n= 73086; H3K4me3 n= 33,270; H3K9me3 n= 86,122; H3K27me3 n= 25,909; H3K36me3 n=
35,877; H3K79me2 n= 33205). e The proportion of hypermethylated probes (n= 46,844 early transition, n= 91,119 late transition, n= 20,297 naive) that
are marked by H3K4me1/2/3, H3K4me1/2/3 alone, or bivalency (H3K4me3 and H3K27me3). f Overlap of late transition hypermethylated probes (n=
91,119) and hypomethylated probes (n= 392,875) with CpG islands (n= 30,344). g Overlap of hypermethylated and hypomethylated probes (as in 1f)
with ENCODE regulatory regions (promoters or enhancers). h Proportion of late transition hypermethylated probes (n= 91,119) that overlap with ENCODE
predicted promoters and enhancers (as defined by ChromHMM in the hESC cell line H1). DMP, differentially methylated probes. For overlap analysis, data
are presented as the log2 corrected fold increase in the observed overlap compared to the mean overlap of 1000 randomly generated loci. ***P < 0.001.
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pluripotent state, it is insufficient for the acquisition of naïve
pluripotency. Collectively, this suggests that the hypermethylation
is more a feature of the heterogeneous intermediate population of
partially reset cells.
Bivalent CGIs that lose H3K4me3 gain DNA methylation. To
investigate the mechanism of bivalent CGI hypermethylation, we
first classified bivalent regions as those possessing H3K4me3 and
H3K27me3 peaks in primed hESCs utilising the ENCODE ChIP-
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Fig. 2 Resetting results in hypermethylation and repression of developmental genes. a GO term analysis of hypermethylated and hypomethylated genes
at the late transition of resetting compared to primed hESCs. A gene was classified as hypermethylated if a hypermethylated probe was present within
1500 bp upstream of the TSS. b Average gene expression for genes that are hypermethylated (average promoter methylation Δβ > 0.1) or hypomethylated
(average promoter methylation Δβ < 0.1) in naïve compared to primed hESCs. Boxes represent the median and interquartile range and error bars represent
the maximum and minimum values. Statistical significance determined via two-tailed paired Wilcoxon test. ***P < 0.001, ****P < 0.0001. CPM, Counts per
Million. c Scatter plot of genes that are hypermethylated and downregulated showing the average promoter methylation (average β-value of CpG probes
within 1500 bp of TSS) versus the log2 CPM (counts per million) for each gene from RNA-seq data. Data for each individual time point are indicated by the
colour key. d Scatter plot showing the average promoter methylation of 21 HOX genes (average β-value of CpG probes within 1500 bp of TSS) versus the
log2 CPM for each gene from RNA-seq data. Data for each individual time point are indicated by the colour key. e GlucMS-qPCR in primed and late
transition hESCs showing the percentage of 5mC (blue) and 5hmC (orange) per CpG. Bars represent the mean of three biological replicates and error bars
represent the SEM. Source data are provided as a Source Data file.
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seq dataset. We observed that only 41% of these loci gain DNA
methylation upon resetting (Fig. 5a), indicating that the presence of
bivalent chromatin is not sufficient for acquiring de novo DNA
methylation upon resetting. We therefore divided all bivalent
regions in primed hESCs into those that do and do not gain
methylation during resetting (hypermethylated regions defined as
>10% increase in naïve vs primed hESC). Taking the nearest gene
to each region (within 1500 bp of the TSS), GO analysis of the
bivalent hypermethylated group showed a strong enrichment for
developmental pathways, while the bivalent non-hypermethylated
group showed much lower enrichment of other biological processes
(Fig. 5a). This points towards common regulation of the develop-
mental genes that exhibit hypermethylation during resetting.
We hypothesised that there are intrinsic differences between
bivalent regions that do and do not gain methylation, which both
begin with similar chromatin states. As DNA methylation and
H3K4me3 are known to be mutually exclusive25, we performed
ChIP-qPCR of H3K4me3 at bivalent DNA regions, across the
time course of resetting. We observed a loss of H3K4me3 at
bivalent regions that become hypermethylated, whilst bivalent
non-hypermethylated regions retain their levels of H3K4me3
(Fig. 5b). In contrast, the levels of H3K27me3 exhibit little
change, despite the presence of DNA methylation (Fig. 5c). While
H3K27me3 and DNA methylation are considered to be mutually
exclusive at CpG rich regions during development26, co-existence
of the two modifications has previously been reported27. It is
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known that loss of H3K4me3 is permissive to the gain of DNA
methylation, but this on its own cannot explain the specific gain
of methylation at these regions, as both DNMT3A and DNMT3B
possess an ADD domain capable of mediating the interaction of
the enzymes with unmethylated H3K425,28–30, and several loci
that have been shown to lose H3K4me3 in naïve hESCs do not
undergo hypermethylation14. Additionally, despite comparable
absolute protein levels of DNMT3A and DNMT3B, as measured
by mass spectrometry (Supplementary Fig. 5g), only DNMT3A
deposits DNA methylation during the early transition of hESC
resetting. Moreover, the strong bias towards developmental genes
suggests that the gradual hypermethylation is not a stochastic
process.
Transcription factors influence hypermethylation. Our data led
us to hypothesise that an additional player, likely a DNA-binding
factor, facilitates DNMT3A-mediated hypermethylation in the
early stages of hESC resetting. To understand the unique prop-
erties of the bivalent hypermethylated group, we performed dif-
ferential motif analysis of these regions, with the bivalent non-
hypermethylated regions as a control set. We identified a number
of motifs corresponding to DNA-binding transcription factors
enriched at regions that undergo hypermethylation (Fig. 6a). To
test whether these proteins are expressed, we performed total
proteomics of primed and early transition hESCs and identified
proteins that were upregulated during the early transition com-
pared to primed hESCs (Fig. 6b). Through cross-comparison of
the two analyses, we short-listed two candidate transcription
factors, SOX15 and NFKB1, which are upregulated during early
resetting and show an enrichment of binding sites at hyper-
methylated regions (Fig. 6a, b). We identified an additional two
candidate transcription factors, FOXC1 and ZFHX3 (Fig. 6a),
which were transcriptionally upregulated during the early tran-
sition based on RNA-seq data but not detected in any samples by
proteomic analysis, likely due to technical limitations of the
method in detecting nuclear transcription factors31. We generated
constitutive knockdown cell lines using two shRNAs targeting
each of the four candidate genes (Supplementary Fig. 8a) and
subjected each of the cell lines to resetting until the early tran-
sition. We measured the expression of naïve pluripotency genes
to test whether the knock down cells undergo resetting similarly
to control cells, and found that their expression is not sig-
nificantly altered in the knockdowns compared to control cells
(Supplementary Fig. 8b). Strikingly, upon resetting, knock down
of each of the transcription factors reduced the level of hyper-
methylation at target loci analysed, suggesting that the tran-
scription factor network active during the early transition of
resetting is involved in bivalent promoter CGI hypermethylation
(Fig. 6c). The impact of each of the knockdowns on DNA
methylation is higher in regions where at least one of the highly
expressed transcription factors are predicted to bind compared to
sites that are not bound by any of the four transcription factors
(Fig. 6c). Interestingly, the reduction in methylation is observed
in each of the transcription factor knockdowns at SOX15 and
NFKB1 predicted binding sites, indicating that the impact is not
limited to the specific binding sites for each transcription factor
(Fig. 6c). This points to a network synergy in preferentially
mediating de novo methylation at these sites. As the reduction in
DNA hypermethylation upon transcription factor knockdown is
only partial; however, this suggests that additional mechanisms
are also at play.
To test whether signalling changes associated with factors
required for induction of the naïve state induction could explain
such a mechanism, we conducted hESC resetting until the early
transition, each time removing one of these factors. Resetting in
the absence of the MEK inhibitor or GSK3β inhibitor or
concomitant removal of both inhibitors still resulted in
hypermethylation at target loci analysed (Fig. 6d), suggesting
that hypermethylation may be coordinated by the overexpressed
NANOG and KLF2 or the associated pluripotency network.
Collectively, these data indicate that upon reprogramming hESCs
to the naïve state, hypermethylation is driven by the transcription
factor network that becomes active upon resetting, and that this is
synchronised by the core pluripotency network.
Resetting-associated hypermethylation is mirrored in cancer.
De novo DNA methylation of bivalent chromatin in the context
of a hypomethylated genome has also been reported in cancer cell
lines and primary tumours32,33. To investigate the link between
the hypermethylation patterns associated with hESC resetting and
the re-emergence of such patterns in cancer, we compared
hypermethylated CpGs at each stage of resetting with regions
previously identified as hypermethylated in B-cell chronic lym-
phocytic leukaemia (B-CLL)34. We observed that the most sub-
stantial overlap is found between hypermethylated CpGs
associated with the late transition of resetting and B-CLL
hypermethylation, corresponding to the peak of hypermethyla-
tion we observe during reprogramming (Supplementary Fig. 9a).
Interestingly, we also see a more significant overlap between
hypermethylated regions in B-CLL or colon cancer34,35 and
resetting-associated hypermethylated CpGs with a low basal
methylation level (<5%) in primed hESCs (Supplementary
Figs 9b, c). These data demonstrate a substantial overlap between
naïve stem cell and cancer hypermethylation.
Fig. 3 Early de novo methylation is dependent on DNMT3A. a, b Heatmaps showing methylation levels in control and DNMT3A/B knock down samples
during resetting. Heatmap shows the top 17,000 CpG differentially methylated probes (DMP; Δβ > 0.1, p < 0.05) in the early transition (Fig. 3a) and late
transition (Fig. 3b) compared to primed hESCs (in wild type early transition (Fig. 3a) or late transition (Fig. 3b) compared to primed hESCs identified in
analysis shown in Fig. 1b). Methylation β-value is indicated by the colour key. c qRT-PCR for naïve pluripotency genes in control and knockdown cells, in
naïve hESCs. Bars represent mean of three biological replicates and error bars represent the SEM. Statistical difference between samples was calculated by
a one-way ANOVA with a Bonferroni post hoc test compared to the control. Human GAPDH was used to normalise expression. d Alkaline phosphatase
activity in knock down and control naïve hESCs. Data shown are the mean of two biological replicates (independent shRNA KD), each with five technical
replicates. Error bars represent SEM. Statistical difference between samples was analysed by a one-way ANOVA with a Bonferroni post hoc test compared
to the control. e Alkaline phosphatase activity in DNMT3A/DNMT3B double knock down and control naïve hESCs. Data shown are the mean of five
replicates. Error bars represent SEM. Statistical difference between samples was analysed by a two-tailed Student’s unpaired t test. f qRT-PCR for naïve
pluripotency genes in control and DNMT3A/DNMT3B double knockdown naïve hESCs. Bars represent the mean of three biological replicates and error
bars represent the SEM. Statistical difference between samples was calculated by a two-tailed Student’s t test. Human GAPDH was used to normalise
expression. g Plot showing % methylation in DNMT3A/DNMT3B double knock down and control cells during resetting. Each dot represents % methylation
of single CpGs (n= 57) from 4 genomic regions analysed by targeted bisulfite sequencing. Red bars represent mean methylation for each sample.
Statistical difference between samples was analysed by a Kruskal–Wallis test, with Dunn’s multiple comparisons post hoc test. For all panels, *P < 0.05,
**P < 0.01, ***P < 0.001, ***(P < 0.0001), N.S. denotes not significant (p > 0.05). Source data are provided as a Source Data file.
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We further hypothesised that cancer cells may recapitulate the
dichotomy between bivalent genes that do and do not become
hypermethylated. To test this, we compared resetting-associated
bivalent hypermethylated and non-hypermethylated CpGs with
data from the cancer genome atlas (TCGA) pan-cancer atlas36,37.
We found a significant gain in methylation between normal and
cancer tissue for bivalent CpGs identified as hypermethylated
during the resetting process, compared to unmethylated bivalent
CpGs (Fig. 7a, Supplementary Fig. 10a). This was consistent across
all cancer types analysed. In addition, when we defined CpGs that
were hypermethylated compared to normal tissues across cancer
types, we found that they were significantly enriched in hESC
hypermethylated bivalent CpGs (Fisher’s test p-value < 2 × 10−16,
percentage fold-change 11.13, Fig. 7b). Similar results were also
observed when defining hypermethylated CpGs for each of the
nine individual tumour types (Fig. 7b). Together these results
indicate that resetting-associated hypermethylation parallels pan-
cancer hypermethylation, though the individual CpGs methylated
in each cancer type vary38. We see no further enrichment of
resetting-associated hypermethylated CpGs with more advanced
stages of cancer (Supplementary Fig. 9d), or with datasets derived
from metastatic tissues (Supplementary Fig. 9e).
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Fig. 4 Hypermethylation is a feature of resetting and is not restricted to emerging naïve cells. a Flow cytometry dot plots showing SUSD2-PE staining on
the x-axis against anti-feeder-APC staining on the y-axis for hESCs during the early and late transition. Boxes indicate SUSD2+ and SUSD2- cell
populations that were sorted. b Plot showing the % methylation in primed, early transition and late transition hESCs, for SUSD2+ and SUSD2− cell
populations. Each dot represents the methylation % of single CpGs (n= 57) from four genomic regions analysed by targeted bisulfite sequencing, and the
red bars represent the mean methylation level for each sample. Statistical difference between samples was analysed by a Kruskal–Wallis test, with Dunn’s
multiple comparisons post hoc test. N.S. denotes not significant (p > 0.05). c qRT-PCR for naïve pluripotency genes in SUSD2+ and SUSD2− cell
populations early and late transition hESCs. Bars represent the mean of three technical replicates and error bars represent SEM. Statistical significance
between samples was analysed with a one-way ANOVA with a Bonferroni post hoc test comparing all samples to each other. Human GAPDH was used to
normalise expression. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, N.S. denotes not significant. Source data are provided as a Source Data file.
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Fig. 5 Bivalent CGIs that lose H3K4me3 gain DNA methylation. a Pie chart showing the proportion of bivalent sites that do and do not gain methylation in
naïve hESCs, and gene ontology analysis of these bivalent hypermethylated and non-hypermethylated genes respectively. b ChIP-qPCR enrichment of
H3K4me3 and (c) H3K27me3 are shown for six candidate bivalent regions (possessing both H3K4me3 and H3K27me3 histone modifications in primed
cells) that become hypermethylated, and for three candidate bivalent regions that fail to become hypermethylated during resetting (bottom row). Data are
shown as the signal enrichment relative to the input sample with bars representing the mean of two independent experiments. Statistical difference
between samples was analysed by a one-way ANOVA test, with Bonferroni post hoc test of each time point compared to primed hESC. * indicates p < 0.05.
Source data are provided as a Source Data file.
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To further investigate the parallels between hypermethylation
in naïve hESCs and cancer, we asked whether the regions
hypermethylated in naïve hESCs were also marked by H3K27me3
in normal human tissues that give rise to cancers. By examining
H3K27me3 ChIP-seq from eight normal tissues, we found that
the regions surrounding hypermethylated CpGs had significantly
higher levels of H3K27me3 than non-hypermethylated CpGs
from naïve hESCs (Fig. 7c, Supplementary Fig. 10b). This
included the HOX loci which we had seen to be strongly
hypermethylated in naïve hESCs as well as loci which are
previously reported as gaining DNA methylation in cancer such
as SFRP1 (Fig. 7d)8.
Together, these results demonstrate that resetting of primed
hESCs to naïve pluripotency and cancer follow similar epigenetic
trajectories, both involving the acquisition of DNA methylation at
developmental gene promoters marked by H3K27me3. There is
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growing evidence in the literature regarding the acquisition of
stem-like properties and expression of pluripotency genes in
cancers10,39. This makes it intriguing to speculate that the
pluripotency network plays a key role in establishing cancer
hypermethylation. Considering the causal relationship between
hypermethylation and acceleration to one-step transformation9,
this warrants further investigation of means to disrupt de novo
accumulation of DNA methylation at CGI promoters.
Discussion
We propose the concept that reprogramming events during
primed to naïve resetting are a fundamental feature of human
cancers and possibly a very early step in cancer evolution.
Although naïve stem cells and cancer cells seem developmentally
distant, our data support the hypothesis that cancers follow an
evolutionary trajectory towards an embryonic stem cell state,
which allows both self-renewal and differentiation10.
We demonstrate the dynamic acquisition of DNA methylation,
primarily at CGI promoters, upon the transition from primed to
naïve pluripotency in hESCs. We observed the highest levels of
hypermethylation in the heterogeneous population of cells pre-
sent during the late transition of resetting. It is worth noting that
during the late transition of resetting, there is population het-
erogeneity as demonstrated by the study of HOX gene promoters,
as well as heterogeneous expression of naïve stem cell markers as
exemplified by the SUSD2 expression, but the hypermethylation
and expression of naïve stem cell markers do not strictly co-
occur. It seems that hypermethylation is a feature of this het-
erogeneous intermediate population of partially reset cells, and it
is partially maintained as the cells stabilise in the naïve state.
We demonstrate that the hypermethylation that we observed
upon the transition from primed to naïve pluripotency mirrors
the frequently observed aberrant hypermethylation in human
cancers. Such parallels have been drawn previously in other
mammalian species and developmental contexts40. However, the
data we present here demonstrate hypermethylation conserved
across in vitro and in vivo human pluripotency17, strengthened
by its reproducibility across multiple in vitro resetting meth-
ods14,16. Moreover, it is notable that we do not observe com-
parable hypermethylation in the mouse ICM or in in vitro mouse
ESCs cultured with 2i inhibitors. This observation has potential
implications for making inferences with regards to epigenetic
processes between species, both in development and in the study
of cancer, as has been noted previously41.
We have observed that bivalent loci are almost exclusively
susceptible to DNA hypermethylation during the transition to
naïve pluripotency. However, not all bivalent loci become
hypermethylated, suggesting that the presence of bivalent chro-
matin is not the only factor required for acquiring de novo DNA
methylation upon resetting. Several studies have demonstrated
that the aberrant gains of DNA methylation observed in cancer
also occur at H3K27me3-marked loci42–44. Loci that gain DNA
methylation in cancer are also enriched in sets of loci that are
bivalent in embryonic stem cells33,42,45. The mechanistic basis of
this relationship is unclear. Although DNMTs can interact with
EZH2 which is responsible for deposition of H3K27me346,
recruitment of DNMT3A by PRC2 is not sufficient to trigger de
novo DNA methylation47. It is particularly noteworthy that
bivalent loci that undergo hypermethylation both upon resetting
and in the context of cancer belong to developmental pathways33,
distinguishing them from other bivalent loci that do not gain
methylation despite having a comparable starting chromatin
configuration.
Our data indicate that DNMT3A is responsible for DNA
hypermethylation during the early transition of primed to naïve
resetting, and that both DNMT3A and DNMT3B contribute to
hypermethylation during the late transition of resetting. At this
stage, the reduction in methylation is only partial upon knock-
down of either enzyme, therefore alternative factors such as the
putative de novo activity of DNMT1 cannot be excluded48. A
knockdown of either DNMT3A or DNMT3B impacted the sta-
bility of the naïve state as measured by alkaline phosphatase
activity, with a knockdown of DNMT3A additionally disrupting
the naïve transcriptional network. Interestingly, a double
knockdown of DNMT3A and DNMT3B had an even greater
impact on the naïve state as measured by alkaline phosphatase
activity, suggesting a synergy between the two de novo methyl-
transferases in influencing either the transition to the naïve state
or naïve cell stability. It remains to be deduced whether
DNMT3A/DNMT3B impact the naïve state through the hyper-
methylation they contribute to or through a non-catalytic role.
Additionally, in order to better understand the functional impact
of resetting-associated hypermethylation, its potential impact on
the differentiation potential of the naïve cells remains to be
investigated independently of the known roles of de novo
methyltransferases in stem cell differentiation.
Our data point towards the transcription factor network
established upon resetting playing a role in the targeting or
recruitment of DNMT3A to loci that gain methylation. Whilst we
cannot currently differentiate between a direct interaction of
DNMT3A with transcription factors or an indirect network-
driven effect on targeting of the enzyme, loci-specific recruitment
of DNMT3A via transcription factors has been previously
demonstrated49 and in vitro data support the ability of DNMT3A
to interact directly with numerous transcription factors50. Our
data are also indicative of the overexpressed NANOG and KLF2
coordinating de novo methylation, however studies have shown
that KLF2 is not expressed in vivo in the human inner cell
mass51,52, where we also observe hypermethylation. Additionally,
we observe comparable hypermethylation in naïve hESCs
Fig. 6 Transcription and pluripotency factors influence hypermethylation. a A selection of the transcription factors with motifs enriched in bivalent
hypermethylated regions, with bivalent non-hypermethylated regions used as a background control. Motif analysis was performed using the analysis of
motif enrichment (AME) tool on the MEME suite. b Volcano plots showing the difference in protein expression in early transition (72 h and 1W) hESCs
compared to primed hESCs (Supplementary Table 6). Each dot represents the log2 fold change based on three biological replicates. Statistical difference
between samples was analysed by a two-tailed student’s t test, corrected for multiple testing. Red dots indicate statistically significant changes
(adjP < 0.05). Proteins of interest are highlighted with coloured and labelled symbols. c Plot showing the % methylation for four different transcription
factor knockdowns and a non-silencing control. Data for each sample are an average of two independent shRNA knockdowns. Each dot represents the
methylation % of a single CpG analysed by targeted bisulfite sequencing, and the red lines represent the mean % methylation level for each sample from
five genomic regions (SOX15 targets; n= 64 CpGs), or four genomic regions (NFKB1 regions; n= 67 CpGs, or regions without TF binding sites for any of
the 4 TFs; n= 66 CpGs). Statistical difference between samples was analysed by a two-way ANOVA test, with Bonferroni post hoc test of each TF knock
down compared to the control. *P < 0.05, **P < 0.01, and ***P < 0.001, ****P < 0.0001. N.S. denotes not significant. d Targeted bisulfite-sequencing of three
genomic regions. Each square represents the methylation % indicated by the colour key of a single CpG. The first column represents data from primed
hESCs, and the subsequent columns represent data from early transition hESCs cultured in a variety of culture conditions indicated by the ± symbols above.
Source data are provided as a Source Data file.
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generated using two transgene-independent methods of resetting.
This collectively suggests that the core pluripotency network, to
which NANOG belongs, is likely responsible for coordinating the
transcriptional changes that drive DNA hypermethylation. There
is growing evidence in the literature regarding the acquisition of
stem-like properties and expression of pluripotency genes
in cancers10,39. This makes it intriguing to speculate that a
transcriptional programme associated with the naïve pluripotency
network could drive a shared mechanism of hypermethylation
during resetting of primed hESCs to naïve pluripotency and in
cancer development, either preceding or in conjunction with
genetic mutations.
Hypermethylation during primed to naïve resetting affects
developmental genes whose expression is generally low and is
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further attenuated upon hypermethylation, as is often observed in
cancer33,38. The function of hypermethylation in cancer remains
a topic of debate. While several studies have shown clear
repressive roles of hypermethylation for individual tumour sup-
pressor genes7,53, it remains less well understood what the pur-
pose of hypermethylation of a large number of loci might be. It
has been proposed that aberrant hypermethylation in cancer may
act to block cellular differentiation, thus enabling cancer cells to
continue to propagate in their more primitive states33,44,54, and
this has been experimentally demonstrated in a recent study9.
During reprogramming of somatic cells to induced pluripotent
stem cells (iPS), global DNA demethylation occurs late55 and is a
bottleneck for efficient reprogramming56. Our data indicate that
in addition to global DNA demethylation which is efficiently
erased in further naïve resetting, gain of DNA methylation in
bivalent developmental gene promoters will lock cells in a pri-
mitive state. The commonality in methylation patterns across
cancer types, each harbouring different driver mutations, suggests
that these methylation changes may by regulated by a common
overarching mechanism and occur early in tumourigenesis, as has
been demonstrated previously in one of the few models of early
cancer development57. In line with this, the notion that cancer
cells follow an evolutionary trajectory towards a stem cell
state10,39 makes the transition from primed to naïve pluripotency
an interesting model to study biological processes such as DNA
methylation that likely occur early during cancer initiation, and
may be analogous to dedifferentiation. Additional molecular
features of the primed to naïve state transition appear analogous
to cancer hallmarks58, such as altered metabolism12, loss of
imprints15, loss of DNA hydroxymethylation59 and genomic
instability11,15,60. Whether they are related to the changing epi-
genetic landscape remains unexplored, but further use of this
model system may shed light on the emergence of these char-
acteristics during cellular transformation. We propose that naïve
resetting may provide a good model system to understand whe-
ther other molecular processes associated with cellular repro-
gramming play a role in tumourigenesis.
Methods
Cell lines. WA09/H9 NK2 primed hESCs were kindly provided by Austin Smith12
with permission from WiCell. All hESCs were cultured on irradiated mouse
embryonic fibroblasts (iMEF). iMEFs were seeded at a density of 1 × 106 cells per 6-
well plate, in 5% O2, 7% CO2 at 37 °C in a humidified incubator.
Cell culture. Primed H9-NK2 cells containing doxycycline-inducible KLF2 and
NANOG transgenes coupled to Venus were maintained in conventional medium
(KSR/FGF) comprised of DMEM/F-12 (Sigma Aldrich) with 20% KSR (Thermo-
Fisher Scientific) and 10 ng per ml basic fibroblast growth factor (bFGF; Pepro-
tech), supplemented with 2mM L-glutamine (ThermoFisher Scientific), 100 μM 2-
mercaptoethanol (2ME) (ThermoFisher Scientific), 1% MEM non-essential amino
acids (ThermoFisher Scientific), and 50 mg per ml Penicillin-Streptomycin. Cul-
tures were passaged every 5–6 days as small clumps by dissociation with a buffer
containing 1 mg per ml Collagenase IV (ThermoFisher Scientific), 0.025% Trypsin
(ThermoFisher Scientific), 1 mM CaCl2 and KSR at a final concentration of 20% in
PBS. Medium was changed daily.
Resetting to the naïve state was carried out as previously described12.
Conventional hESCs were dissociated to single cells with trypsin and re-plated in
the presence of 10 µM Rho-associated kinase inhibitor (ROCKi [Y-27632]; Sigma
Aldrich). After 24 h, media was changed to primed media with 1 µM doxycycline
(Sigma Alrich). The following day, media was changed to 2iL+dox media
composed of 50% DMEM/F12 and 50% Neurobasal (ThermoFisher Scientific)
supplemented with 2mM L-glutamine, 100 µM 2ME, N2 (ThermoFisher Scientific),
B27 (ThermoFisher Scientific), 1 µM PD0325901 (StemCell Technologies), 1 µM
CHIR99021 (StemCell Technologies), human recombinant LIF (Peprotech), 1x
Penicillin-Streptomycin and 1 µM doxycycline. Media was changed daily. Cells
were split every 4–5 days after dissociation to single cells using Accutase (Sigma
Aldrich). After 2 weeks, doxycycline was withdrawn and PKC inhibitor Gö6983
(Sigma Aldrich) was added at a concentration of 5 µM. Cells in 2iL+Gö were split
every 4–5 days after dissociation to single cells using Accutase.
Stable knock down or overexpression cell line generation. Short hairpin RNA
(shRNA) constructs were obtained from Dharmacon in the TRC pLKO.1 lentiviral
vector. Sequences are listed in Supplementary Table 1. Knockdown of DNMT3A2
was not carried out due to an inability to design an effective shRNA against its
single unique exon. Entry clone for overexpression of TET1 was obtained from
Harvard PlasmID Repository (TET1 in pENTR223; HsCD00399189) and a
recombination reaction was performed with the pLenti CMV puro DEST (w118-1)
destination vector with Gateway LR clonase II (ThermoFisher Scientific) to gen-
erate expression vectors. To generate lentiviral particles, HEK293T cells were
transfected with the shRNA plasmid or expression vector for a target gene, the
packaging construct pCMV Δ8.91, and a vesicular stomatitis virus glycoprotein
(VSV-G) containing envelope expressing plasmid pMD2.G, using jetPrime (Poly-
plus) at a ratio of 1:2. Primed hESCs were treated with 6 µg per ml polybrene
(Sigma Aldrich), transduced with filtered lentiviral particles, and stable hESC
knock down or overexpression cell lines were generated by puromycin selection
(1 µg per ml) of successful integrants.
Western blotting. Whole cell lysates were extracted in RIPA buffer (Sigma
Aldrich), with protease inhibitor cocktail (Sigma Aldrich). Proteins (concentration
determined by BCA assay) were separated by electrophoresis on a 4–12% Bis–Tris
gel in MOPS running buffer (ThermoFisher Scientific) and then transferred to
polyvinylidene difluoride (PVDF) membranes (Merck Millipore). Membranes were
blocked with 5% skimmed milk for 45 min at room temperature and incubated
overnight at 4 °C with primary antibody (TET1: Source Bioscience; GTX124207 at
1:1000 and GAPDH: Cell Signalling Technologies; 2118S at 1:2500) in blocking
buffer. Membranes were incubated for 1 h at room temperature with horseradish
peroxidase-conjugated secondary antibodies sheep-anti-mouse IgG or sheep-anti-
rabbit IgG (1:5,000; GE Healthcare; NA931, NA934). Membranes were washed in
0.1% Tween-20 in PBS (PBST), and detection was performed with enhanced
chemiluminescence (ThermoFisher Scientific), with visualisation on the Amersham
Imager 600 (GE Healthcare). Uncropped blots are provided in Supplementary
Fig. 11.
qPCR. Cells were dissociated to single cells using Accutase and serially plated for 2
h to eliminate excess iMEFs. Total RNA was isolated from pelleted hESCs using the
Direct-zol RNA mini-prep kit (Zymo) and treated with the DNA-free™ DNA
removal kit (ThermoFisher Scientific). Complementary DNA (cDNA) was made
using a high-capacity RNA to cDNA kit (ThermoFisher Scientific). Real-time PCR
was carried out using one-step Sybr green reaction mix (Bio-Rad) on the CFX384
Touch™ Real Time PCR detection system (Bio-Rad). An endogenous control
(GAPDH) was used to normalise expression. Primer sequences are listed in Sup-
plementary Table 2.
Chromatin immunoprecipitation. Cells were cross-linked with 1% formaldehyde
for 10 min at room temperature with gentle rocking, after which the formaldehyde
Fig. 7 Resetting-associated hypermethylation is mirrored in cancer. a Differences in mean methylation level between matched normal tissue and tumour
samples of bivalent CpGs identified as hypermethylated (N= 23,123) or not hypermethylated (N= 25,977) during the transition to the naïve state in
hESCs. Data are presented for 592 individuals, separated by tumour location. P-values determined via paired Wilcoxon test (two-sided). CpGs used for
analysis were filtered for those that are unmethylated in primed hESCs (β < 0.3). Lines=median; Box=25th–75th percentile; whiskers=1.5× interquartile
range from box. b Overlap of CpGs hypermethylated in cancers with bivalent CpGs hypermethylated during hESC resetting. Values for all cancers were
generated by testing all cancer samples against all normal samples. P-values are determined using Fisher’s exact tests (two-sided). c Heatmap of
H3K27me3 distribution in 250 bp windows around each hESC Hypermethylated CpG in normal colon (N= 26180), ordered by total H3K27me3 reads
within 5 kb. Peaks are taken from ENCODE (Supplementary Table 8). Scale is in normalised reads per million. d Selected genomic regions containing hESC
Hypermethylated CpGs marked by H3K27me3 in the normal colon (highlighted light orange). Mean methylation in normal colon and colorectal tumours
from TCGA, as well as the difference between them are shown in black. hESC Hypermethylated CpGs are shown in blue, and H3K27me3 ChIP reads from
ENCODE are shown in orange (Supplementary Table 8). Scale for methylation data is 0–100%. Scale for methylation difference is −50 to 50%. Scale for
H3K27me3 is 0 to 30 normalised reads per million reads.
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was quenched with 1.25 M glycine. Chromatin was then extracted from the cross-
linked cells using the chromatin extraction kit (Abcam), as per the manufacturer’s
instructions. The extracted chromatin was then fractionated by sonication at 4° (12
cycles of 15 s on, 60 s off; Diagenode Bioruptor® Plus). The size of the sonicated
chromatin was then checked by agarose gel electrophoresis. Chromatin immuno-
precipitation was carried out using the ChIP—One Step kit (Abcam) with a starting
total of 5 µg of chromatin. Immunoprecipitation was carried out as per the man-
ufacturer’s instructions and the following quantites of antibody were used for
immunoprecipitation; H3K4me3 0.5μg (Abcam; ab8580), H3K27me3 2 μg (Abcam;
ab195477). As a loading control for assessing immunoprecipitation we isolated
input DNA for each sample, which represent the starting quantity of chromatin
prior to immunoprecipitation. Input and immunoprecipitated DNA were quanti-
fied by real-time PCR, and data are shown as the % enrichment relative to the input
for each sample. Primer sequences are listed in Table 3.
Bisulfite Sequencing Analysis. Bismark coverage files downloaded from GEO
were uploaded into SeqMonk (v1.41.0), where the genomes were binned into 300
bp probe windows. Methylation quantitation was carried out using the ‘Bisulphite
methylation over features’ pipeline in SeqMonk (v1.41.0), with a 300 bp probe
carried forward if it contained at least 5 CpGs each with at least 3 counts. Motif
enrichment analysis was performed using the analysis of motif enrichment (AME)
tool on the MEME suite (v5.0.4)61, searching against the human HOCOMOCO
(v11 FULL) database. Sequences were scored using the average odds score and
motif enrichment calculated using Fisher’s exact test.
Overlap analysis. Overlap analysis was performed in R using the package regi-
oneR (Version 3.8: https://bioconductor.org/packages/release/bioc/html/regioneR.
html). Overlap was performed using the ‘overlapPermTest’ function with 1000
permutations. Random regions were generated for the hg19 genome using the
‘circularRandomizeRegions’ function. Random loci generation was restricted to loci
present in the Illumina EPIC array (for overlaps performed with Illumina EPIC
array probes) or to regions with a (G+ C) fraction >0.55 and a CpG observed-to-
expected ratio >0.6 (for overlaps performed with bisulfite sequencing data).
ENCODE and ChromHMM data for the H1 hESC cell line were downloaded from
the UCSC genome browser. For ENCODE data, StdPk files were downloaded for
each histone modification and genomic coordinates extracted (as BED files) for use
in the overlap analysis.
Mass spectrometry of nucleosides. Genomic DNA was digested using DNA
Degradase Plus (Zymo Research) according to the manufacturer’s instructions and
nucleosides were analysed by LC-MS/MS on a Q-Exactive mass spectrometer
(Thermo Scientific) fitted with a nanoelectrospray ion-source (Proxeon). All
samples and standards had a heavy isotope-labelled nucleoside mix added prior to
mass spectral analysis (2′-deoxycytidine-13C1, 15N2 (Santa Cruz), 5-(methyl-2H3)-
2′-deoxycytidine (Santa Cruz), 5-(hydroxymethyl)-2′-deoxycytidine-2H3 (Toronto
Research Chemicals). MS2 data for 5hmC, 5mC and C were acquired with both the
endogenous and corresponding heavy-labelled nucleoside parent ions simulta-
neously selected for fragmentation using a 5 Th isolation window with a 1.5 Th
offset. Parent ions were fragmented by Higher-energy Collisional Dissociation
(HCD) with a relative collision energy of 10%, and a resolution setting of 70,000 for
MS2 spectra. Peak areas from extracted ion chromatograms of the relevant frag-
ment ions, relative to their corresponding heavy isotope-labelled internal standards,
were quantified against a six-point serial 2-fold dilution calibration curve, with
triplicate runs for all samples and standards.
Targeted bisulfite sequencing. Bisulfite PCR primers were designed against an in
silico bisulfite converted reference sequence using the Bisulfite Primer Seeker
software (Zymo) or Methprimer (Urogene), and universal Illumina adapter
sequences were added to the 5’ end of each primer. Cells were dissociated to single
cells using Accutase and serially plated for 2 h to eliminate excess iMEFs. DNA was
isolated from pelleted cells using the PureLink Genomic DNA mini kit (Ther-
moFisher Scientific). Bisulfite conversion of DNA was carried out using the
Imprint® DNA Modification kit (Sigma Aldrich), following the manufacturer’s
instructions. The modified DNA was amplified using the loci-specific bisulfite PCR
primers (listed in Supplementary Table 4) and HotStar Taq DNA Polymerase
(Qiagen). The PCR conditions were as follows: 95 °C for 15 min; 94 °C for 30
seconds; 56 °C for 30 s; 72 °C for 1 min; Repeat steps 2–4 29×; 72 °C for 10 min;
Hold 12 °C. PCR products were purified using SPRI beads (Agencourt AMPure XP,
Beckman Coulter). Amplicons were PCR amplified with 8 cycles using a universal
Illumina forward primer and an indexed reverse primer and quantified with the
Kapa Library quantification kit for Illumina (Roche). For larger experiments,
multiplex targeted bisulfite sequencing was performed using the 48×48 layout on
the Fluidigm C1 system (Fluidigm), coupled with Illumina MiSeq sequencing.
Fluidigm primers are listed in Supplementary Table 5. Amplicons from a single
sample were pooled and sequencing was performed on an Illumina MiSeq with
150 bp paired-end reads, using v3 chemistry, at Barts and the London Genome
Centre (London, UK). Reads were quality trimmed and mapped to a personalised
human genome composed of amplicon sequences, using Bismark (v.0.19.0), fol-
lowed by extraction of methylation calls.
Infinium MethylationEPIC BeadChip assay. Genomic DNA was extracted using
the PureLink Genomic DNA mini kit (ThermoFisher Scientific). Bisulfite con-
version of DNA was carried out using the Imprint® DNA Modification kit (Sigma
Aldrich), following the manufacturer’s instructions. Infinium MethylationEPIC
BeadChip assay (Illumina) was performed according to manufacturer instructions
by Barts and the London Genome Centre (London, UK). The Bioconductor
package ChAMP (version 2.11.3: https://bioconductor.org/packages/release/bioc/
html/ChAMP.html) was used to process raw Infinium idat files using the GRCh37
human genome manifest file.
TCGA analysis. Illumina 450K DNAMethylation data spanning 396965 CpGs and
9664 samples was downloaded from the Pan Cancer Atlas (https://gdc.cancer.gov/
about-data/publications/pancanatlas). All samples from individuals without both a
tumour and normal tissue sample were removed. Samples from tumour types with
less than 30 individuals were removed. In order to assess only CpGs deemed
“bivalent”, CpGs outside of regions that showed a peak of H3K27me3 and
H3K4me3 in ENCODE H1 hESCs were removed. For this analysis, raw infinium
IDAT files from the hESC resetting experiment were processed using minfi and
normalised via the single-sample Noob method62. CpGs used for analysis were
filtered for those that are unmethylated in primed hESCs (mean beta < 0.3).
Unmethylated probes were restricted to those CpGs with mean Beta < 0.3 during
the primed to naïve transition. Hypermethylated hESC probes were defined using
ChAMP and restricted to those CpGs with ΔBeta > 0.1 in either the early transi-
tion, late transition or naïve state. Probes hypermethylated in cancer were also
defined using ChAMP, and similarly restricted to those CpGs with ΔBeta > 0.1
between normal tissue and tumour samples. The overlap enrichment of cancer
hypermethylated and hESC hypermethylated regions was determined via Fisher’s
exact test. For the creation of heatmaps, data were first ordered by sample based on
mean methylation of all CpGs, and then by CpG based on mean methylation across
all samples of every cancer type. Statistical significance was calculated using a
paired Wilcoxon test.
Human tissue H3K27me3 analysis. H3K27me3 and control read alignments were
downloaded as BAM files for each normal human tissue examined from ENCODE
(https://www.encodeproject.org/)63,64 that corresponded to the cancers profiled by
TCGA, except HSNC for which no obvious corresponding normal sample was
available. Bigwig files for genome browser visualisation and peaks of H3K27me3
for comparison were obtained in the same way. ENCODE IDs for each experiment
and data file can be found in Supplementary Data 1. To examine H3K27me3 levels
around naïve hypermethylated CpGs, windows of 500 bp was defined centred
around each CpG. ChIP-seq read counts/window were calculated using BEDtools’
coverage function. Read counts were scaled to counts per 10 million based on total
number of mapped reads/sample and divided by the input read count to provide a
normalised read count. To prevent windows with zero reads in the input sample
generating a normalised count of infinity, an offset of 0.5 was added to all windows
prior to scaling and input normalisation. Regions where coverage was 0 in all
samples were removed from the analysis. A similar procedure was used to generate
heatmaps of H3K27me3 levels, using multiple 250 bp windows to span 5 kb on
either side of each CpG. Colour scales for ChIP-seq heatmaps range from the
minimum to the 90% quantile of the normalised read count.
Analysis of 5hmC by glucMS-qPCR. Genomic DNA was treated with T4 Phage β-
glucosyltransferase (T4-BGT; NEB) according to the manufacturer’s instructions.
Glucosylated genomic DNA was digested with 10 U of either HpaII, MspI or no
enzyme (mock digestion) at 37 °C overnight, followed by inactivation for 20 min at
80 °C. The HpaII- and MspI-resistant fraction was quantified by qPCR using
primers designed around at least one HpaII/MspI site, and normalising to the
mock digestion control. Resistance to MspI directly translates into percentage of
5hmC, whereas 5mC levels were obtained by subtracting the 5hmC contribution
from the total HpaII resistance. Primers used are listed in Supplementary Table 6.
Mass spectrometry-based proteomics. Cells from three independent biological
replicates per condition were washed twice with ice cold PBS supplemented with 1
mM Na3VO4 and 1 mM NaF, lysed in urea buffer (8 M urea in 20 mM in HEPES
pH 8.0, 1 mM Na3VO4, 1 mM NaF, 1 mM Na4P2O7 and 1 mM sodium β-glycer-
ophosphate) for 30 min and homogenised by sonication (15 cycles of 30 s on 30 s
off; Diagenode Bioruptor® Plus). Insoluble material was removed by centrifugation
at 20,000g and protein levels in the cell extracts were quantified by bicinchoninic
acid (BCA) analysis. For trypsin digestion, 100 µg of protein was reduced and
alkylated by sequential incubation with 10 mM DTT and 16.6 mM iodoacetamyde
for 1 h and 30 min, respectively. Urea concentration was diluted to 2M with 20
mM HEPES (pH 8.0), 80 µL of preconditioned trypsin beads [(50% slurry of
TLCK-trypsin (Thermo-Fisher Scientific; Cat. #20230)] were added and samples
were incubated for 16 h at 37 °C with agitation. Peptide solutions were desalted
using 10 mg OASIS-HLB cartridges (Waters, Manchester, UK). Briefly, OASIS
cartridges were accommodated in a vacuum manifold (−5 mmHg), activated with
1 mL ACN and equilibrated with 1.5 mL washing solution (1% ACN, 0.1% TFA).
Peptides were loaded into the cartridges, washed with 1 mL of washing solution,
eluted with 500 µL of ACN solution (30% ACN, 0.1% TFA), dried in a speed vac
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(RVC 2-25, Martin Christ Gefriertrocknungsanlagen) and stored at −80 °C. Dried
peptides were dissolved in 0.1% TFA and analysed by nanoflow ultimate 3000 RSL
nano instrument coupled to a Q Exactive plus mass spectrometer (Thermo Fisher
Scientific). Gradient elution was from 3 to 35% solvent B in 120 min at a flow rate
300 nL/min with solvent A being used to balance the mobile phase (buffer A was
0.1% formic acid in water and B was 0.1% formic acid in acetonitrile). The spray
voltage was 1.95 kV and the capillary temperature was set to 255 °C. The Q-
Exactive plus was operated in data dependent mode with one survey MS scan
followed by 15 MS/MS scans. The full scans were acquired in the mass analyser at
375–1500m/z with the resolution of 70,000 and the MS/MS scans were obtained
with a resolution of 17,500. Overall duty cycle generated chromatographic peaks of
approximately 30 s at the base, which allowed the construction of extracted ion
chromatograms (XICs) with at least 10 data points. Mascot Daemon 2.5.0 was used
to automate peptide identification from MS data. Peak list files (MGFs) from RAW
data were generated with Mascot Distiller v2.5.1 and loaded into the Mascot search
engine (v2.5) in order to match MS/MS data to peptides. Searches were performed
against the SwissProt Database (release December 2015) with a FDR of ~1% and
restricted to the human entries. Mass tolerance of ±10 ppm for the MS scans and
±25 mmu for the MS/MS scans, 2 trypsin missed cleavages, carbamidomethyl Cys
as a fixed modification and PyroGlu on N-terminal Gln and oxidation of Met as
variable modifications were allowed. The in-house developed Pescal software was
used for label-free peptide quantification as described before65, XICs for all the
peptides identified across all samples were constructed with ±2 min and ±7 ppm
retention time and mass windows, respectively. Peak areas from all XICs were
calculated. The maximum intensity value for the two technical replicates was
selected and used for further analysis. Intensity values for each peptide were
normalised to total sample intensity. Statistical significance was calculated using
two tail unpaired Student’s t test. Multiplicity correction was performed by
applying the Benjamini–Hochberg method on the p-values, to control the false
discovery rate (FDR). Differences were considered significant when FDR < 0.05.
Proteins with a Mascot score > 40 were used for analysis. Data are available in
Supplementary Data 2.
RNA-sequencing. Total RNA was extracted using Direct-zol RNA mini kit
(Zymo) and DNase treated (ThermoFisher Scientific), before mRNA was isolated
from 500 ng of total RNA using Dynabeads mRNA DIRECT purification kit
(ThermoFisher Scientific) and fragmented with RNA fragmentation reagent
(ThermoFisher Scientific). First strand cDNA synthesis was performed with
SuperScript III First-Strand Synthesis System and 3 μg μl−1 random hexamers
(ThermoFisher Scientific) followed by second strand synthesis with DNA poly-
merase I and RNase H. After purification using SPRI beads, the double stranded
cDNA was ligated to in house designed adapters (based on TruSeq Indexed
adapters (Illumina)) using NEBNext Ultra II (NEB) followed by 15 cycles of
amplification and library purification. Library size distribution and molarity was
assessed by the DNA 1000 assay on the 2100 Bioanalyzer (Agilent), and libraries
were quantified with the Kapa Library quantification kit for Illumina (Roche).
Sequencing was performed on an Illumina NextSeq with 75 bp paired-end
sequencing at Barts and the London Genome Centre (London, UK). Read quality
was determined using FASTQC. Genomic mapping of short reads was performed
using hisat2 (v. 2.1.0) to the human genome (GRCh38). Reads were counted for
each sample using FeatureCounts (Subread, v. 1.6.3)66. RNA-sequencing analysis
was performed using the R package EdgeR (v3.18.1)67. Upregulated and down-
regulated genes were called as those with Benjamini-Hochberg corrected FDR <
0.05 and a log2 fold change > 1. Pathway enrichment analysis was performed using
DAVID Bioinformatics Resources68,69.
Alkaline phosphatase assay. Cells were seeded a 96-well plate. After 24 h, the
Amplite™ Colorimetric Alkaline Phosphatase Assay kit (Stratech) was used to
measure alkaline phosphatase activity according to manufacturer’s instructions.
Flow cytometry, fluorescence-activated cell sorting (FACS). Cells were dis-
sociated to single cells with Accutase and washed with 3%FCS/PBS, before being
blocked in 10% FCS/PBS. Cells were resuspended in 2.5ul SUSD2-PE antibody
(Biolegend; 327406) and 5ul anti-feeder-APC antibody (Miltenyi Biotec; 130-120-
802) for 15 min at 4 °C in the dark. Alternatively, following 1 h pulse labelling with
10um BrdU, cells were fixed, permeabilised, blocked and stained using the APC
BrdU Flow Kit (BD Pharminogen) following manufacturer’s instructions, with the
addition of 5ul of anti-feeder-PE antibody (Miltenyi Biotec; 130-120-166). Cells
were wash twice in 3% FCS/PBS and then stained with DAPI for 15 min at 4 °C in
the dark. Samples were either analysed on an LSR Fortessa cell analyser (BD
Biosciences) or FACS sorted on the BD FACS Aria Fusion cell sorter. Flow cyto-
metry data analysis was carried out using FlowJo Version 10 software.
Statistical analysis. Significance testing was performed using Prism (v.7.04,
v.8.4.2) and Student’s t test, one-way ANOVA or two-way ANOVA with Bon-
ferroni post hoc tests as specified in the figure legends. Where applicable, data are
plotted as mean ± SEM. Representative data are shown where experiments were
repeated at least twice with similar results.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The data that support this work are available from the corresponding author upon
reasonable request. The mass spectrometry data have been deposited to the
ProteomeXchange Consortium via the PRIDE partner repository with the dataset
identifier PXD019893. The sequencing data have been deposited in the Gene Expression
Omnibus under GSE128130. Additional data used include ENCODE, ChromHMM and
TCGA pan-cancer data, HOCOMOCO (v11 FULL), SwissProt (Dec 2015 release). Data
for human naive resetting methods were obtained from GSE60945, GSE76970,
GSE90168, data for mouse 2i and serum ESCs from GSE42923, and data for human and
mouse in vivo development from GSE34864 and GSE49828. Source data are provided
with this paper.
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